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GRAPHICAL ABSTRACTBackground: Monogenic autoinflammatory disorders are
characterized by dysregulation of the innate immune system, for
example by gain-of-function mutations in inflammasome-
forming proteins, such as NOD-like receptor family CARD-
containing 4 protein (NLRC4).
Objective: Here we investigate the mechanism by which a novel
mutation in the leucine-rich repeat (LRR) domain of NLRC4
(c.G1965C, p.W655C) contributes to autoinflammatory disease.
Methods: We studied 2 unrelated patients with early-onset
macrophage activation syndrome harboring the same de novo
mutation in NLRC4. In vitro inflammasome complex formation
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Abbreviations used
AIFEC: Autoinflammation with infantile enterocolitis
ASC: Apoptosis-associated Speck-like protein containing a
caspase recruitment domain
CARD: Caspase activation and recruitment domain
CRISPR: Clustered Regularly Interspaced Short Palindromic
Repeats
CSF: Cerebrospinal fluid
HD: Hinge domain
IL-18BP: IL-18 binding protein
KO: Knockout
LRR: Leucine-rich repeat
MAS: Macrophage activation syndrome
NAIP: NLR family apoptosis inhibitor protein
NBD: Nucleotide-binding domain
NLRC4: NOD-like receptor family CARD-containing 4 protein
NLRC4-AID: NLRC4-associated autoinflammatory disorder
NLRP3: NOD-like receptor family, pyrin domain containing 3
NOD: Nucleotide-binding oligomerization domain
T3SS: Type 3 secretion system
WT: Wild-type
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2 MOGHADDAS ET AL2 interfaces on the opposing LRR domain of the oligomer. One
key set of residues (p.D1010, p.D1011, p.L1012, and p.I1015)
participated in LRR-LRR oligomerization when triggered by
mutant NLRC4 or type 3 secretion system effector (PrgI)
stimulation of the NLRC4 inflammasome complex.
Conclusion: This is the first report of a mutation in the LRR
domain of NLRC4 causing autoinflammatory disease.
c.G1965C/p.W655C NLRC4 increased inflammasome activation
in vitro. Data generated from various NLRC4 mutations
provides evidence that the LRR-LRR interface has an
important and previously unrecognized role in oligomerization
of the NLRC4 inflammasome complex. (J Allergy Clin Immunol
2018;nnn:nnn-nnn.)
Key words: Autoinflammatory disease, periodic fever syndrome,
NLRC4, macrophage activation syndrome, inflammasome, Nod-like
receptor, IPAF, IL-18
Inflammasomes are large multimeric complexes formed in
response to pathogen-associated or damage-associated molecular
patterns. Some innate immune sensors oligomerize with the
adaptor protein apoptosis-associated speck-like protein contain-
ing a caspase recruitment domain (ASC) and caspase-1 to form a
platform for the cleavage of pro–IL-1b and pro–IL-18 to their
active forms. Gain-of-function mutations in inflammasome-
forming proteins are a major cause of monogenic autoinflamma-
tory disorders, a heterogeneous group of conditions characterized
by innate immune dysregulation.
NOD-like receptor family caspase activation and recruitment
domain (CARD)–containing 4 protein (NLRC4) forms an inflam-
masome in response to type 3 secretion system (T3SS) proteins
from invading gram-negative bacteria, such as Salmonella species.
Components of T3SS are recognized by cytosolic sensors known
as NLR family apoptosis inhibitor proteins (NAIPs).1-3 NAIP pro-
teins associate with NLRC4, initiating a conformational change
that allows for NLRC4 oligomerization through self-propagation
of the nucleotide-binding oligomerization domain (NOD).4,5
Mutations in the NOD of NLRC4 result in autoinflammation,
with a spectrum of clinical manifestations ranging from cold-
induced urticaria to life-threatening macrophage activation syn-
drome (MAS) with severe enterocolitis.6-10 NLRC4-associated
autoinflammatory disorders (NLRC4-AIDs) are characterized
by high levels of free IL-18 in the serum of patients, distinguish-
ing it from other monogenic inflammasomopathies, such as Fa-
milial Mediterranean Fever or Cryopyrin Associated Periodic
Syndrome. Importantly, successful treatment with a recombinant
IL-18 binding protein (IL-18BP) has been reported in 1 patient
with autoinflammation with infantile enterocolitis (AIFEC;
OMIM 616050), an NLRC4-AID.11
Here we identify a previously unknown mutation in the leucine-
rich repeat (LRR) domain of NLRC4 in 2 unrelated patients with
MAS. This is the first report of such a mutation in NLRC4, and we
provide in vitro evidence of the importance of LRR-LRR interac-
tions in the disease pathophysiology in these patients.METHODS
Patient and study approval
Informed consent for genetic sequencing was obtained from the patients’
guardians. Patient P1 was recruited through routine care. Patient P2 and age-and sex-matched control subjects were recruited through the Guangzhou
Women and Children’s Medical Center Ethics Committee (2016021602).
Further informed consent was obtained for publication of case descriptions
and clinical images.Genetic analysis
Genomic DNA was extracted from whole blood using the QIAamp DNA
Micro Kit (56304; Qiagen, Hilden, Germany). Targeted sequencing was
performed on patient P1. NLRC4 was amplified by means of PCR and
sequenced using the Sanger method and primers listed in Table E1 in this ar-
ticle’s Online Repository at www.jacionline.org. Whole-exome sequencing
was performed on patient P2 and patient P2’s family members using the Agi-
lent SureSelect Human All Exon V6 kit (Agilent Technologies, Santa Clara,
Calif) sequenced on an Illumina platform (Illumina, San Diego, Calif). Bioin-
formatics analysis with readmapping and variant calling was performed using
the Genome Analysis Toolkit Haplotype Caller. The variant of interest was
confirmed with Sanger sequencing.Serum cytokine analysis
For patient P1, serumwas diluted in sample buffer and assayed inmultiplex
on a Luminex Magpix system (Bio-Rad Laboratories, Hercules, Calif).
Human IL-18BPa beads were generated with magnetic beads (Bio-Rad
Laboratories) conjugated to clone MAB1192 and detected with clone
BAF119 (both from R&D Systems, Minneapolis, Minn). Bioplex Pro group
II cytokine standard was used for IL-18, whereas recombinant human IL-
18BPa–Fc (R&DSystems) was used for IL-18BP. Patient P2’s serum cytokine
levels were quantified by using an ELISA for IL-1b (CHE001; 4A Biotech,
Beijing, China) and IL-18 (CHE007; 4A Biotech), according to the
manufacturer’s guidelines.Generation of NLRC4-deficient cells
The method of generating knockout (KO) cells using Clustered Regularly
Interspaced Short Palindromic Repeats (CRISPR)/Cas9 techniques, as well
as lentivirus production, has been previously described.12,13 The single
guide RNA constructs used to make CASPASE1 KO, CASPASE8 KO, and
PYCARD KO cells have been previously described.14-16 Genetic deletion
of NLRC4 was achieved using single guide RNA oligonucleotides targeting
exon 2 (see Table E1).
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Lentiviral constructs were generated by means of amplification of NLRC4
cDNAwith Phusion DNA polymerase (M0530S; New England BioLabs, Ips-
wich, Mass) using primers flanked by restriction enzyme sequences, which al-
lowed for cloning into the pFUGW backbone (see Table E1).17 Both pFUGW
and amplified cDNAwere digested with AgeI-HF (R3552) and BamH1-HF re-
striction enzymes (R3136; New England BioLabs), followed by agarose gel
electrophoresis and DNA extraction. The vector and insert were ligated with
T4 DNA Ligase (B0202S; New England BioLabs).
Site-directed mutagenesis
Site-directedmutagenesis was performed with the QuickChange Lightning
Kit (210519-5; Agilent Technologies), according to the manufacturer’s
instructions. Mutations were introduced to constructs by using the oligonu-
cleotides listed in Table E1.
Cell-culture procedures
Human THP-1 and HEK293T cells were grown at 378C in a humidified
atmosphere of air with 10% CO2. THP-1 cells were maintained in HT RPMI
(1% [wt/vol] RPMI-1640, 0.2% [wt/vol] NaHCO3, 0.011% [wt/vol]
C3H3NaO3, 0.1% [wt/vol] streptomycin, and 100 U/mL penicillin) supple-
mented with 10% (vol/vol) FBS (Sigma-Aldrich, St Louis, Mo).
HEK293T cells were maintained in Dulbecco modified Eagle medium
(1% [wt/vol] D-glucose, 0.11% [wt/vol] sodium pyruvate, 0.1% [wt/vol]
streptomycin, and 100 U/mL penicillin) supplemented with 10% (vol/vol)
FBS (Sigma-Aldrich).Transduction of KO cell lines
NLRC4KO cells were reconstituted using third-generation lentiviral vector
transduction. We were not able to generate stable cell lines carrying patho-
genic NLRC4 mutations because of high levels of spontaneous cell death.
As a result, lentiviral transduction was undertaken before each experiment,
as previously described.18 THP-1 cells, 23 106, were infected per condition,
with 13 106 cells per well in a 6-well plate. One milliliter of viral supernatant
was added to each well and supplemented with 2.5 mL of RPMI and 8 mg/mL
polybrene, followed by centrifugation for 3 hours at 840g at 328C. Cells were
incubated overnight at 378C, and the following day, they were washed in PBS
and reseeded in fresh complete RPMI. After a further 24 hours, cells were
seeded for experiments, and protein expression was determined on whole-
cell lysates.Cell stimulation
THP-1 monocytes underwent retroviral transduction with pMXsIG_
PrgI_GFP.19 Briefly, 3 3 106 HEK293T cells were seeded in 10-cm Petri
dishes. After adherence, cells were transfected with Lipofectamine 2000
(Life Technologies, Grand Island, NY) and pMXsIG_PrgI_GFP (10 mg)
along with pGag-pol (5 mg) and pVSV-G (500 ng). After a media change
to complete RPMI plus 10% FBS at 24 hours, viral supernatants were
collected at 48 hours and stored at 2808C until required. THP-1 cells
were plated in 96-well plates to a final density of 5 3 104 cells per well.
Priming was performed with the synthetic Toll-like receptor 2/1 agonist
Pam3CSK4 (InvivoGen, San Diego, Calif) at a final concentration of
100 ng/mL for 3 hours. A titration of viral supernatant was used, with
RPMI added to bring the volume of each well to 100 mL. Polybrene was
added to a final concentration of 8 mg/mL. Supernatants were collected at
24 hours for cytokine quantification by means of ELISA, and cells were
stained with propidium iodide (1 mg/mL; Sigma-Aldrich) to quantify cell
death by using flow cytometry. NOD-like receptor family, pyrin domain con-
taining 3 (NLRP3) was activated by treating cells with nigericin (10 mmol/L;
InvivoGen) for 1 hour before collection of supernatant and cell death anal-
ysis. Where indicated, the NLRP3 inhibitor MCC950 (20 ng/mL) was
used 30 minutes before stimulation with PrgI or nigericin or, in the case
of mutant cell lines, after priming.Cytokine quantification from cell-culture
supernatants
The presence of cytokines in supernatants was assessed bymeans of ELISA
for IL-1b and IL-18 using DY201 and DY008 kits, respectively (R&D
Systems), according to the manufacturer’s guidelines.Western blot analysis
THP-1 and HEK293T cells were lysed with RIPA buffer supplemented
with cOmplete protease inhibitors (11697498001; Roche Biochemicals,
Mannheim, Germany). Whole-cell lysates were incubated on ice for
30 minutes and clarified by means of centrifugation. Whole-cell lysates
were eluted with SDS-PAGE sample buffer, resolved on Novex 4-12%
SDS-PAGE gels with MES running buffer, and subsequently transferred
onto nitrocellulose membranes. Membranes were blocked overnight in 3%
BSA plus 0.1% Tris-buffered saline–Tween 20 at room temperature for
1 hour and then probed overnight at 48C with primary antibodies,
including a-NLRC4 (rabbit a-NLRC4; D5Y8E; Cell Signaling Technol-
ogy, Danvers, Mass), a–caspase-1 (mouse a–caspase-1 p20; AdipoGen,
San Diego, Calif), a-ASC (rabbit a-ASC; sc-22514; Santa Cruz Biotech-
nology, Dallas, Tex), a–caspase-8 (mouse a–caspase-8; #9746; Cell
Signaling Technology), and a-actin (goat a-actin; sc-1616; Santa Cruz
Biotechnology).Time-of-flight inflammasome evaluation
Flow cytometry for quantification of ASC speck formation by time-of-
flight inflammasome evaluation (TOFIE) was used as a surrogate marker of
inflammasome activation.20 HEK293T cells were transfected with 5 ng of
GFP-ASC and 10 ng of pCR3_NLRC4_VSV. ASC speck formation was
quantified using flow cytometry 16 hours after transfection. For examination
of the response to T3SS proteins, TOFIE was conducted in HEK293T cells
stably expressing ASC-RFP through retroviral transduction.21 These cells
were transfected with 10 ng of pCR3_NLRC4_VSV, as well as variable
amounts of pMXsIG_PrgI_GFP and pCS2_hNAIP_myc, as described in the
relevant figure legends.22Structural analysis
Previously published Protein Data Bank files 4KXF,23 3JBL,4 and 6B5B24
were used to generate ribbon figures of NLRC4’s structure in the PyMOL
Molecular Graphics System (Version 2.0; Schr€odinger, New York, NY). The
NLRC4 active and inactive conformations were compared by aligning the
LRR domains.Statistical analysis
Prism software (GraphPad Software, La Jolla, Calif) was used to perform
2-tailed t tests. Data were pooled from at least 3 independent experiments and
represented as means 6 SEMs, unless otherwise specified.RESULTS
Case 1
Patient P1 presented at age 11 days with high-grade fever,
urticaria-like rash (Fig 1, A), and increased acute-phase reactant
C-reactive protein levels (Fig 1, E). Broad-spectrum antibiotic
therapy was initiated for suspected neonatal sepsis. Multiple
blood and cerebrospinal fluid (CSF) cultures remained sterile.
Despite antimicrobial therapy, the patient continued to deterio-
rate, with development of thrombocytopenia and acute renal
injury (Fig 1, F and H) necessitating intermittent peritoneal
dialysis. The patient had hepatosplenomegaly, and the
urticaria-like rash evolved to a combination of petechiae and
ecchymosis (Fig 1, B-D). Progressive pancytopenia, as well
FIG 1. Clinical manifestations and biochemical analysis of patient P1. A and B, Dermatologic signs evolved
from the initial presentation of urticaria-like rash (Fig 1, A) to petechiae and ecchymosis (Fig 1, B). C and D,
Ultrasonographic images indicate hepatomegaly (Fig 1, C) and splenomegaly (Fig 1, D). E and F, Increased
C-reactive protein (CRP) levels (Fig 1, E) and platelet counts (Fig 1, F) were improved transiently with intra-
venous immunoglobulin and dexamethasone. G and I, Ferritin levels (Fig 1, G) remained markedly
increased despite treatment with numerous immunomodulatory agents (Fig 1, I). H, Acute renal injury
and response to peritoneal dialysis monitored with serum creatinine levels. J, Serum IL-18, IL-18BP, and
free IL-18 levels were assessed on days 12 and 35. PRBC, Packed red blood cells.
J ALLERGY CLIN IMMUNOL
nnn 2018
4 MOGHADDAS ET ALas an increase in soluble IL-2 receptor, ferritin, transaminases,
and triglyceride levels (Fig 1, G, and see Fig E1 in this article’s
Online Repository at www.jacionline.org) provided biochem-
ical evidence of MAS, which was confirmed on bone marrow
biopsy. Multiple anti-inflammatory and immunomodulatory
agents were used, including high-dose corticosteroids and the
terminal complement component inhibitor eculizumab (300-
mg single dose) without a significant effect (Fig 1, I). The pa-
tient had severe secretory diarrhea despite therapy, prompting
consideration of the diagnosis of AIFEC. The IL-1 receptor
antagonist anakinra (10 mg/d increased to 20 mg/d after
18 days) was used, again without clinical response, and a
dose of tocilizumab (40 mg) was given, although with only
short-term improvement.
The clinical situation deteriorated, with development of diffuse
mucosal hemorrhage complicated by bladder clots and obstruc-
tive renal failure requiring surgical decompression. Eight weeks
after presentation and after quantification of free IL-18 in the
serum, a trial of recombinant IL-18BP was initiated at 2 mg/kg
subcutaneously every 48 hours (Fig 1, J). Although there was
slight improvement in diarrhea after 5 doses, thrombocytopenia
persisted, and inflammatory markers remained increased. Based
on the severity of symptoms, end-organ damage, and familywishes, active care was withdrawn, and the patient died at age
11 weeks, 9 weeks after admission.Case 2
Patient P2 presented at age 18 months with persistent fever
despite treatment for bronchopneumonia with oral cephalosporin.
The patient had a history of neonatal sepsis diagnosed at day 3 of
life, 2 episodes of bronchopneumonia, and intestinal intussus-
ception requiring surgical intervention at 11 months of age. In the
6 days before this admission, patient P2 experienced cough,
dyspnea, wheezing, diarrhea, abdominal pain, andmaculopapular
skin rash. On admission, the patient was febrile at 38.88C, with
examination revealing symmetric breath sounds with transmitted
upper airway sounds and hepatomegaly. Chest radiography
confirmed bronchopneumonia, and abdominal radiography re-
vealed an enlarged liver (Fig 2, A and B). C-reactive protein levels
were markedly increased (Fig 2, C), prompting commencement
of treatment with intravenous ceftriaxone.
Given the history of recurrent infections, primary immunode-
ficiency was suspected, and intravenous immunoglobulin treat-
ment was initiated. Evaluation for primary immunodeficiency
revealed increased IgE levels, and the diagnosis of hyper-IgE
FIG 2. Clinical manifestations and biochemical analysis of patient P2. A, Chest radiograph documenting
bronchopneumonia. B, Abdominal radiograph demonstrating hepatomegaly. C and D, C-reactive protein
(CRP) levels (Fig 2, C) remained increased throughout admission with progressive thrombocytopenia (Fig
2, D). E and F, Serum IL-1b (Fig 2, E) and IL-18 (Fig 2, F) from healthy control subjects (HC), parents, and
the patient.
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pository at www.jacionline.org). Persistent fever and altered
conscious state prompted consideration of central nervous system
infection. CSF culture grew Sphingomonas paucimobilis, and tar-
geted antimicrobial treatment was commenced. Despite this, pa-
tient P2 remained febrile, with deterioration of conscious state,
progressive hepatosplenomegaly, lymphadenopathy, and throm-
bocytopenia (Fig 2, D). Subsequent CSF cultures remained ster-
ile. The serum ferritin level at this time was markedly increased
at 16,500 mg/mL (normal range, 7-140 mg/mL), as were transam-
inase and triglyceride levels, prompting a diagnosis of MAS.
Treatment with methylprednisolone at 2.5 mg/kg/d was
commenced; however, the patient died 16 days after admission.
Retrospective analysis of serum from day 15 showed patient P2
had markedly increased total IL-18 levels (Fig 2, E and F).Genetic analysis
Patient P1 underwent targeted Sanger sequencing of NLRC4
because of clinical suspicion of AIFEC. Sequencing revealed het-
erozygous NLRC4 c.1965G>C transition encoding for the
p.W655C variant. Patient P2 had the same variant detected by
whole-exome sequencing, which was subsequently confirmed
using Sanger sequencing. The sequence of STAT3 in patient P2
was specifically reviewed, and no mutations were identified. No
immediate family members of either patient had this substitution,
suggesting de novomutations (Fig 3, A). NLRC4 p.W655 is high-
ly conserved across species (Fig 3, B), and p.W655C has not been
documented in the Genome Aggregation Database (gnomAD).25
Although predicted to be benign (PolyPhen-2) or tolerated
(SIFT), the suspicion of pathogenicity was such that further eval-
uation ensued.26,27
FIG 3. Pedigree of families. A, Patients P1 and P2 both carried a G>C transition at c.1965 NLRC4 encoding a
tryptophan-to-cysteine substitution at p.W655. Solid symbols represent affected subjects, and open sym-
bols represent unaffected subjects. Squares, Male subjects; circles, female subjects. B, Sequence alignment
across species shows that this is a highly conserved locus.
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NLRC4 consists of an N-terminal CARD, a nucleotide-binding
domain (NBD), 2 hinge domains (HDs; HD1 and HD2), a winged
helix domain (WHD), and a C-terminal LRR domain (Fig 4, A).
The structure of murine NLRC4, which shares 75% sequence
identity with human NLRC4, suggests that NLRC4 exists in an
ADP-dependent autoinhibited monomeric conformation, with
the C-terminal LRR domain occluding the central NBD (Fig 4,
B).23 NLRC4 activation results in a conformational change that
exposes the NBD (Fig 4,C).24 p.W655C resides in the LRR distal
to the currently knownmutations, which are all located around the
ADP-binding regions (Fig 4, A-C).6-10,28,29p.W655C NLRC4 results in increased ASC speck
formation
A hallmark of inflammasome activation within a single cell is
formation of the so-called ASC speck. We performed experi-
ments to determine whether expression of p.W655C NLRC4
resulted in increased ASC speck formation compared with wild-
type (WT) NLRC4. Flow cytometry was used to quantify ASC
speck formation as a marker for inflammasome assembly and
activation. HEK293T cells were transiently transfected with
ASC-GFP and various mutant forms of NLRC4. We observed
significantly increased ASC speck formation in cells transfected
with p.W655C NLRC4 compared with WT NLRC4. The same
was also true for the other known NLRC4 mutants, except
p.H443P, when expressed at similar levels (Fig 4, D and E).
These data indicate that p.W655C increases inflammasome
assembly.p.W655C NLRC4 causes increased IL-1b and IL-18
release and pyroptosis
NLRC4-deficienct THP-1 monocyte–like cells were generated
by using CRISPR/Cas9 gene editing techniques to model
p.W655C NLRC4 in a relevant human cell line (see Fig E2 in
this article’s Online Repository at www.jacionline.org). NLRC4
KO THP-1 cells were transduced with lentiviral constructs car-
rying NLRC4 cDNA with various mutations. THP-1 cells tran-
siently transduced with mutant NLRC4 exhibited increased cell
death and released more IL-1b and IL-18 compared with WT
NLRC4 (Fig 5, A-C). Cell death and cytokine response were
similar in p.W655C NLRC4 compared with other known
disease-causing mutations. p.H443P NLRC4 was expressed at
lower levels and released significantly less IL-1b than the other
mutations (Fig 5, D). Caspase-1 deletion significantly reduced
IL-1b and IL-18 secretion and decreased cell death (Fig 5, E-G).Increased IL-18 secretion, but not cell death, is
dependent on ASC
The requirement of ASC in patients with NLRC4-AIDs was
addressed by Romberg et al10 using a HEK293T overexpression
system, and they determined that ASC was required for mutant
NLRC4-associated caspase-1 cleavage. To further explore the
requirement of ASC in a monocytic cell line, we transduced
PYCARDKOTHP-1 cells withWTor mutant NLRC4. Cell death
seen with p.W655C NLRC4 was not decreased significantly by
deletion of ASC, but IL-18 was markedly reduced to levels
similar to those seen in CASPASE1 KO cells (Fig 5, E-G). There
was also a trend toward reduced IL-1b secretion. This suggests
FIG 4. p.W655 is located in the LRR domain of NLRC4. A, Schematic representation of NLRC4 domains, with
the variant of interest shown in green. B and C, Ribbon representation of secondary structure of autoinhi-
bited (PDB Code 4KXF23; Fig 4, B) and active (PDB Code 6B5B24; Fig 4, C) NLRC4. p.W655C NLRC4 is dis-
played in stick format in green. D and E, ASC speck quantification of WT and NLRC4 mutants by using
flow cytometry (Fig 4, D), with NLRC4 expression in whole-cell lysate assessed by using Western blotting
(Fig 4, E). Data are pooled from 5 independent experiments: *P < .05, **P < .01, ***P < .001, and
****P < .0001. NBD, Nucleotide binding domain; WHD, winged helix domain.
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FIG 5. Effects of p.W655C NLRC4 on cytokine production and cell death. NLRC4 KO THP-1 monocytes were
transduced with lentivirus coding for WT or various NLRC4mutations (as indicated). Twenty-four hours af-
ter transduction, cells were plated and treated with Pam3CSK4. A-C, After 24 hours, propidium iodine (PI)
staining was assessed by using flow cytometry to quantify cell death (Fig 5, A), and IL-1b (Fig 5, B) and
IL-18 (Fig 5, C) secretion was measured by means of ELISA. D, Expression of NLRC4 under each condition
was qualified by means of Western blotting of whole-cell lysates. E-H, CASPASE1, PYCARD, or CASPASE8
KO THP-1 monocytes were transduced with WT or p.W655C NLRC4, and assessment of cell death (Fig 5, E)
and IL-1b (Fig 5, F) and IL-18 (Fig 5, G) secretion was undertaken after treatment with Pam3CSK4, with
expression of NLRC4 determined by using Western blotting (Fig 5, H). THP-1 cells, along with NLRC4,
CASPASE1, PYCARD, or CASPASE8 KO THP-1 monocytes, were primed for 3 hours with Pam3CSK4 and
infected with 2 amounts of retrovirus expressing PrgI needle protein. I-K, After 24 hours, cell death (Fig 5,
I) and IL-1b (Fig 5, J) and IL-18 (Fig 5, K) secretion were assessed with flow cytometry and ELISA,
respectively. Data were pooled from at least 3 independent experiments. *P < .05, **P < .01, and ***P < .001.
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ated with this mutant, but not pyroptosis, is dependent on ASC.
Thus cytokine release and cell death might either depend on
distinct and individual pathways or require different thresholds
of caspase-1 activity.Increased IL-1b and IL-18 secretion and cell death
are not dependent on caspase-8 or NLRP3
Caspase-8 is a downstream effector of NLRC4-induced
cytokine response in the context of Salmonella typhimurium
infection in a murine model.30 When transduced with
NLRC4 constructs, CASPASE8 KO THP-1 cells exhibit
increased rather than abrogated cell death and IL-1b and
IL-18 secretion (Fig 5, E-H), indicating that caspase-8 does
not contribute to the increased inflammatory response but
might rather have a regulatory role. Stimulation of CASPASE8
KO cells with nigericin, an activator of NLRP3, also resulted
in increased IL-1b release when compared with THP-1–Cas9
control cells (see Fig E3, D, in this article’s Online Repository
at www.jacionline.org), suggesting that the increase is not
specific to NLRC4. When THP-1 cells were stimulated with
PrgI, a T3SS protein, ASC contributed to cell death andcytokine response and caspase-8 contributed to cell death
and IL-18 response, suggesting that the mechanism of
activation might differ between pathogenic NLRC4 mutations
and the physiologic response to T3SS proteins (Fig 5, I-J).
The presence of NLRP3 and NLRC4 in a single inflammasome
complex has been reported in the setting of S typhimurium infec-
tion.31,32 Therefore we explored the potential contribution of
NLRP3 to p.W655C NLRC4–associated inflammation by treat-
ing cells with the specific small-molecule NLRP3 inhibitor
MCC950.33 Cell death and IL-1b and IL-18 release were un-
changed in response to coculture with MCC950 (see Fig E3).
Because MCC950 completely blocked NLRP3 activation by ni-
gericin, the presented data indicate that NLRP3 does not play a
significant role in the autoinflammation seen in association with
p.W655C NLRC4.p.W655 does not tolerate substitution
To investigate the potential mechanisms of increased NLRC4
activation, we considered formation of a disulfide link, given that
cysteine contains a sulfhydryl group that, when oxidized, might
create a disulfide bond. Western blots performed in reducing or
nonreducing conditions did not change the size of NLRC4,
FIG 6. Assessment of local conformational changes in response to NLRC4 activation. A, Ribbon represen-
tation of the region surrounding p.W655 displaying conformational changes between autoinhibited (dark
purple) and active (light purple) NLRC4. p.W655 NLRC4 is highlighted in green. B, Residues potentially in-
teracting with p.W655 at rest and maintaining NLRC4 in an autoinhibited conformation. C, Flow cytometric
ASC speck quantification of WT and p.W655C NLRC4, along with mutations created to explore potential
local interactions. Data were pooled from 3 independent experiments. ***P < .001 and ****P < .0001.
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mations because of a new disulfide bond (see Fig E4, A, in this ar-
ticle’s Online Repository at www.jacionline.org). This was
further explored through manipulation of the cysteine residue at
position p.605 because this was considered to be the most likely
residue with which p.W655C can form a disulfide bond. Mutation
of p.C605 to alanine or serine did not change the levels of ASC
speck formation (see Fig E4, B), further arguing against the for-
mation of a disulfide bond as the mechanism of increased
p.W655C NLRC4 activation.
In response to NLRC4 activation, p.W655 undergoes a small
change in orientation (Fig 6, A). We investigated the possibility
that p.W655 interacts with an amino acid in close proximity to
keep NLRC4 in an autoinhibited conformation and whether sub-
stitution with cysteine results in loss of this interaction and sub-
sequent activation (Fig 6, B). Substitution of the glutamic acid at
p.600 to alanine or glycine to explore changes in polarity and
size or the glutamine at p.657 to glutamic acid to explore
changes in charge did not result in increased ASC speck forma-
tion (Fig 6, C). These findings suggest that disruption of local
interactions when NLRC4 is in an autoinhibited conformation
are unlikely to explain the increased activation in p.W655C
NLRC4. Next, we asked whether increased NLRC4 activation
was specific to the cysteine substitution at this residue. Trypto-
phan was mutated to alanine, aspartic acid, or serine to explore
changes in size, charge, and polarity. Each of these mutations
resulted in increased ASC speck formation when compared
with WT NLRC4 (Fig 6, C), suggesting that p.W655 does not
tolerate substitution and that changes are not specific to a
cysteine at p.655.The LRR interface is important for inflammasome
assembly
Next, we considered whether an LRR-LRR interface was
important for the increased inflammasome activation seen with
p.W655C. Several mutations to alanine were made in 2 separate
a-helices to remove potential binding surfaces in the adjacent
LRR of the activated NLRC4 oligomer (LRR1: p.D1010,
p.D1011, p.L1012, and p.I1015; LRR2: p.R985, p.S988, and
p.Q989; Fig 7, A). Cell death and cytokine responses of LRR1 and
LRR2 NLRC4 transduced into NLRC4 KO THP-1–Cas9 cellsshowed no difference when compared with WT NLRC4 (Fig 7,
B). Combining p.W655C with either LRR1 or LRR2 reduced
cell death and IL-1b and IL-18 secretion to levels comparable
with WT NLRC4 (Fig 7, B-D). This suggests that the
characteristics of the adjacent LRR and potential interactions at
this interface are important for increased activation seen with
p.W655C. Of note, addition of LRR1 mutations to a
representative disease-causing mutation involving either the
NBD, HD1, or WHD of NLRC4 resulted in significantly reduced
cytokine secretion and cell death, with the exception of p.H443P
NLRC4, implying that LRR1 might be important for NLRC4
oligomerization. On the other hand, combining LRR2with known
disease-causing mutations did not reduce inflammasome
activation, suggesting that LRR2 is an interface that might only
be engaged by the specific p.W655C NLRC4 mutation. This
possibility was further explored through stimulation of WT,
LRR1, or LRR2 NLRC42expressing THP-1–Cas9 cells with
the T3SS effector PrgI (Fig 7, E-G). Indeed, cells expressing
LRR1 NLRC4 released significantly less IL-1b in response to
PrgI compared with WT NLRC4 (Fig 7, F), even when increased
amounts of LRR1 NLRC4 were expressed in the cells.
We conclude that LRR1 is important for maximal physiologic
oligomerization of the NLRC4 inflammasome complex.DISCUSSION
We report the unfavorable clinical course of 2 children with
MAS associated with the c.G1965C/p.W655C mutation in
NLRC4 and provide evidence of pathogenicity for this mutation
in both a HEK293T overexpression model and genetically modi-
fied THP-1 cell models.
The clinical and biochemical evidence of MAS and gastroin-
testinal symptoms in our patients was similar to the original
description of AIFEC.6,10 Clinical symptoms and resistance to
multiple immunomodulatory agents together with increased
serum levels of free IL-18 prompted consideration of the diag-
nosis of AIFEC and a trial of IL-18BP in patient P1. However, se-
vere end-organ damage after a prolonged disease course resulted
in discontinuation of IL-18BP treatment and a change to palliative
care. Although serum ferritin levels decreased in response to
treatment with IL-18BP, effects cannot be adequately assessed af-
ter only 5 doses (Fig 1, G). Thus comparison with a recent case
FIG 7. Assessment of p.W655 NLRC4 in oligomerized form. A, Ribbon representation of NLRC4 in the oligo-
merized state (PDB Code 6B5B24) with magnified inset areas highlighting 2 potential regions of interaction
with p.W655 (LRR1 and LRR2).NLRC4 KO THP-1 cells transduced with lentiviral constructs expressingWT or
mutant NLRC4 combined with LRR1 or LRR2 mutations. B-D, Twenty-four hours after transduction, cells
were primed with Pam3CSK4 for 24 hours, and then propidium iodine (PI) staining was assessed by using
flow cytometry to quantify cell death (Fig 7, B), and IL-1b (Fig 7, C) and IL-18 (Fig 7, D) secretion were
measured by ELISA. NLRC4 KO THP-1 cells were transduced with 1 mL of WT NLRC4, LRR1 NLRC4, or
LRR2 NLRC4 virus or 2 mL of LRR1 NLRC4 virus (LRR1 [32]). E-G, After 24 hours, cells were infected with
a retroviral PrgI construct and cell death (Fig 7, E), and IL-1b (Fig 7, F) and IL-18 (Fig 7, G) secretion assessed
the following day. H and I, NLRC4 expression was assessed by using Western blot analysis. Data were
pooled from at least 3 independent experiments. *P < .05 and **P < .01.
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kinig is problematic.34 The duration of clinical disease and/or the
severity of illness with organ damage before treatment initiation
or differences in IL-18BP and free IL-18 might explain variable
outcomes. Both patients with the p.W655CNLRC4mutation suc-
cumbed to disease very early in life. Poor outcomes in the 2 re-
ported patients with p.W655C NLRC4 mutations might reflect
unfavorable genotype-phenotype correlations in patients with
this form of NLRC4-AID.
The detection of S paucimobilis in the CSF of patient P2 raises
the question of an immunodeficiency associated with p.W655C
NLRC4. This gram-negative bacillus is generally considered to
be of low virulence.35 A series of case reports of bacteremia
with S paucimobilis, usually from intravenous administration of
contaminated solutions in a health care setting, indicate that pa-
tients respond well to treatment, and only 1 pediatric and 1 adult
case have been associated with mortality from this organism.36,37
The possibility of an associated immune deficiency is raised by
the severity of illness, as well as evidence of a poor IL-1b, IL-
18, and cell death response of monocytes from patients with
AIFEC to S typhimurim and Pseudomonas aeruginosa when
compared with healthy control subjects.10 There has also been a
report of activation of NLRC4 resulting in dampening of Toll-
like receptor 5–induced antibody response to flagella, raising
the possibility of an associated immunodeficiency.38 However,
patient P2 cleared the organism with appropriate antimicrobial
therapy as repeat CSF cultures were negative. Therefore it is diffi-
cult to conclude that the response to this flagellated organism was
impaired. Alternatively, it might be that this infection with S pau-
cimobilis triggered MAS. A further consideration is the possibil-
ity of sample contamination rather than a true infection.
This previously unknown c.G1965C/p.W655C NLRC4 muta-
tion causes increased inflammasome formation, cell death, and
proinflammatory cytokine production in a caspase-1–dependent
manner (Fig 5, E-G). The role of ASC in the response of
NLRC4 to infection has been explored in murine gram-negative
infection models, including S typhimurium, P aeruginosa,
Legionella pneumophila, and Shigella species. In these disease
models NLRC4 was required for both pyroptosis and cytokine
production, but ASC was only required for cytokine re-
sponses.39-43 Here we show that in human cells ASC is required
for IL-18 and possibly IL-1b production but not cell death. There-
fore induction of cell death and cytokine production by caspase-1
might involve distinct pathways, with ASC required for one but
not the other. Alternately, the level of caspase-1 activity required
for cell death, and possibly IL-1b production, might be lower than
that required for IL-18 production. NLRC4 might associate with
caspase-1 independently of ASC because it contains a CARD
domain. However, ASC may still be required for optimal inflam-
masome assembly and caspase-1 activation, and the absence of
ASC might result in cell death without a maximal cytokine
response.
Interestingly, p.H443P NLRC4 caused less ASC speck forma-
tion in the HEK293T system, as well as lower cytokine response,
compared with other known disease-causing mutations in a THP-
1 cell system. To date, p.H443P NLRC4 has been described in 1
Japanese family with familial cold autoinflammatory syndrome.8
No family member had MAS, which is consistent with a less se-
vere clinical presentation.
This is the first report of a mutation in the LRR of NLRC4 that
causes disease. By exchanging p.W655 for aspartic acid, alanine,or serine, we deduced that the size of tryptophan at p.W655 is
potentially important for keeping NLRC4 in an autoinhibited
conformation. Tryptophan is the largest amino acid, and substi-
tution with smaller amino acids resulted in similarly increased
ASC speck formation, regardless of changes to charge or polarity.
Furthermore, our data suggest that a structural change at
position 655 creates a binding interface together with LRR
domain residues p.R985, p.S988, and p.Q989 in the active
oligomeric structure (Fig 7, A). Changes to the LRR adjacent to
p.W655 disrupt this interface and abrogate increased inflamma-
some activation caused by the p.W655C mutation. The LRR1
interface (p.D1010, p.D1011, p.L1012, p.I1015) appears to be
important for oligomerization of NLRC4, as the cytokine and
cell death response of known mutations is abrogated when com-
bined with LRR1, as is the response to PrgI.
Taken together, this study highlights the broad spectrum of
clinical features and the severity of disease that can be seen in
patients with NLRC4-AIDs. We model the first LRR mutation in
NLRC4, p.W655C, to evaluate pathogenicity and show that the
location of this residue is important in the mechanism of
inflammasome assembly. Severe disease presentation and poor
disease outcomes in both patients might reflect particularly
unfavorable genotype-phenotype correlation for the p.W655C
NLRC4 mutation in patients with this syndrome.
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Key messages
d Two patients with p.W655C NLRC4 had fatal MAS and
significantly increased serum IL-18 levels.
d De novo c.G1965C NLRC4 mutation encoding p.W655C
NLRC4 is the first mutation reported in the LRR domain
of NLRC4 to cause disease.
d An LRR-LRR interface is important for NLRC4 inflam-
masome activation by NLRC4-AID mutations and the
T3SS effector PrgI.REFERENCES
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FIG E1. Biochemical and hematologic profile of patient P1. A-G, Alanine aminotransferase (ALT; Fig E1, A),
aspartate aminotransferase (AST; Fig E1, B), soluble IL-2 receptor (sIL-2R; Fig E1, C), triglycerides (Fig E1, D),
lactate dehydrogenase (LDH; Fig E1, E), international normalized ratio (INR; Fig E1, F), and leukocyte count
(Fig E1,G) displayed over time.H, Treatment over the same time period. IVIG, Intravenous immunoglobulin;
PRBC, packed red blood cell.
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FIG E2. T3SS selection and validation of NLRC4 KO THP-1 cells. HEK293T cells were transfected with WT
NLRC4, as well as increasing amounts of human NAIP (hNAIP) and the T3SS needle protein PrgI. A, Flow
cytometric analysis of ASC speck formation shows that WT NLRC4 is needed for ASC speck formation
and that hNAIP is required for ASC specks to increase in response to low amounts of PrgI. B, Various
T3SS proteins were transfected into HEK293T cells in addition toWT NLRC4 and hNAIP to ensure specificity
of response. The ASC speck response is specific to the only needle protein tested, PrgI. C, THP-1–Cas9 cells
infected with inducible single guide RNA targeting exon 2 of NLRC4 were treated with doxycycline for
72 hours and expression of NLRC4 assessed with Western blotting performed on whole-cell lysates after
48 hours of rest. Cells were then primed with Pam3CSK4 and infected with 2 amounts of retrovirus express-
ing PrgI needle protein. D-F, After 24 hours of assessment of cell death (Fig E2, D), IL-1b (Fig E2, E) and IL-18
(Fig E2, F) secretion was undertaken.
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FIG E3. Role of NLRP3 in p.W655C NLRC42associated inflammation. NLRC4 KO THP-1 cells were trans-
duced lentivirally with WT or p.W655C NLRC4. A-C, Contribution of NLRP3 to cell death and cytokine
response was determined by using MCC950 at 20 ng/mL with cell death (Fig E3, A), and IL-1b (Fig E3, B)
and IL-18 (Fig E3, C) secretion was assessed after 24 hours of treatment. D, IL-1b response to nigericin
(10 mmol/L) for 1 hour with and without MCC950 pretreatment in cell lines used. Data were pooled from
at least 3 independent experiments.
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FIG E4. Investigation of potential disulfide bonds. A, HEK293T cells were transfected with WT NLRC4 or
p.W655C NLRC4. After 24 hours, cells were lysed in either reducing (presence of dithiothreitol [DTT]) or
nonreducing conditions. Protein size was compared between conditions. An antibody-only control was
used to ensure that a band could be detected in both conditions. Data are representative of 3 independent
experiments. B,ASC speck quantification using flow cytometry ofWT and p.W655CNLRC4with andwithout
manipulation of p.C605 NLRC4. Data were pooled from 3 independent experiments.
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TABLE E1. Primers
Primer Sequence (59/ 3)
Amplification
Lenti_blast _F GCGGATCCAGCAGTTACTAGTTTAAAAGC
Lenti_blast_R CACAGGACCGGTTCTAGAGCGCTGCCACCATGAATTTCATAAAGGACAATAG
CRISPR sgRNA
Exon 2_1 TCCCTCAGCTGCTCCACGCGGTGA
Exon 2_1 AAACTCACCGCGTGGAGCAGCTGA
Sequencing
NLRC4_ex3_F TGA ATA GCC AGG GGC TTT GAG
NLRC4_ex3_R ACT GGT CAG AGG AAG CCA TG
NLRC4_ex4_F AGT AGA GAC AGG GTT TCA CTG
NLRC4_ex4_R TAT CAA AGG CCA CTG CCA GG
NLRC4_ex5_Fa AGC TCA GAA CTG GGA AAG GAC
NLRC4_ex5_Ra TGC TTC CTG ATT GTG CCA GG
NLRC4_ex5_Fa1 AAG TGC AAG GCT CTG ACC AAG
NLRC4_ex5_Ra1 TCA TGA GAT TCC TCA AGC ACC TG
NLRC4_ex5_Fa2 AGT TTG GTG CCC TGA CTG C
NLRC4_ex5_Ra2 TGC TGA GTC TTC GTC CTG C
NLRC4_ex5_Fa3 ACT GCA GGA TGT GTC CAG C
NLRC4_ex5_Ra3 TGA AGT CCA GGG CAC TTG C
NLRC4_ex5_Fa4 AGT ACA TCC AAA TCA GCC CTG
NLRC4_ex5_Ra4 TTG CAG CCT GAG GCT TGT G
NLRC4_ex5_Fa5 AAC CTA CAT TCC CAG CAG GG
NLRC4_ex5_Ra5 ACC TTG CAG GCT GTA ACC C
NLRC4_ex6_F ACA GTG AAG TAT AAT GCC CAT CTC
NLRC4_ex6_R ACA TCC TTG CCT TGT GCA GAC
NLRC4_ex7_F AGT CGC TGC AGG AAG AAC ATG
NLRC4_ex7_R TGT GTG GCA AGT TTC AAG CAC C
NLRC4_ex8_F TAC ACC TAC ACC AGA GCC TTT G
NLRC4_ex8_R AGG AGG GTG CAT CTA GTA AGG
NLRC4_ex9_F AGA TTG AGT AGG CTG CAG AGC
NLRC4_ex9_R AGA ATC TGA AGG AAG GCC AGT G
NLRC4_ex10_F TCT GAG GCA AAG CAC TGG TTC
NLRC4_ex10_R TCC TAG TAG GAG AGC TAA GAC AC
Forward CAAAGTGTGAAAAACACCACTGAGC
Forward GTGTTTTTTGACTTTAGTAC
Forward AGGACTTGAATGGACAAAGTC
Mutagenesis
p.W655C TATCTTTGTTCTTCAACTGCAAGCAGGAATTCAGGACTC
p.W655C GAGTCCTGAATTCCTGCTTGCAGTTGAAGAACAAAGATA
p.T177A TCGCTGCAGCAGAGCGGACTTGCCTTTGC
p.T177A GCAAAGGCAAGTCCGCTCTGCTGCAGCGA
p.S171F TTGCCTTTGCCAAATTCCCCTTCAATGATGCAGGGG
p.S171F CCCCTGCATCATTGAAGGGGAATTTGGCAAAGGCAA
p.W655A GAGTCCTGAATTCCTGCTTCGCGTTGAAGAACAAAGATACAG
p.W655A CTGTATCTTTGTTCTTCAACGCGAAGCAGGAATTCAGGACTC
p.W655S AGTCCTGAATTCCTGCTTCGAGTTGAAGAACAAAGATAC
p.W655S GTATCTTTGTTCTTCAACTCGAAGCAGGAATTCAGGACT
p.S533A TTTTCACACTTTGCAAAGCTTCCTGTCTCCAGAGAGG
p.S533A CCTCTCTGGAGACAGGAAGCTTTGCAAAGTGTGAAAA
p.E600A ACTTGCACAATTGGGCAAATGTGCAAAGAAGTCAAATAAGTAATCG
p.E600A CGATTACTTATTTGACTTCTTTGCACATTTGCCCAATTGTGCAAGT
p.E600G ACTTGCACAATTGGGCAAATGTCCAAAGAAGTCAAATAAGTAATCG
p.E600G CGATTACTTATTTGACTTCTTTGGACATTTGCCCAATTGTGCAAGT
LRR1 CAGTTACTAGTTTAAAAGCACCTGTAGCAACACTGGCAGCAGCATCATCAAATTGCCACCCAACAAGCC
LRR1 GGCTTGTTGGGTGGCAATTTGATGATGCTGCTGCCAGTGTTGCTACAGGTGCTTTTAAACTAGTAACTG
LRR2 CTTCTTGCAGAAAAGTTAACTTGGATAACACTGCGGCAAGTTTTGCGACTAATGCTGGATCAGGTAGAAATTCTTTAG
LRR2 CTAAAGAATTTCTACCTGATCCAGCATTAGTCGCAAAACTTGCCGCAGTGTTATCCAAGTTAACTTTTCTGCAAGAAG
p.V341A TTGCACAAGTGATGACCGCAAAGAGAGGGGTCTTC
p.V341A GAAGACCCCTCTCTTTGCGGTCATCACTTGTGCAA
p.T337S TGAGGAATCTCATGAAGTCCCCTCTCTTTGTGGTC
p.T337S GACCACAAAGAGAGGGGACTTCATGAGATTCCTCA
p.Q657A TTTGTTCTTCAACTGGAAGGCGGAATTCAGGACTCTGGAG
p.Q657A CTCCAGAGTCCTGAATTCCGCCTTCCAGTTGAAGAACAAA
sgRNA, Single guide RNA.
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TABLE E2. Immunologic workup of patient P2
Test Result Reference range
Immunoglobulins
IgG (g/L) 23.5 4.5-9.5
IgA (g/L) 0.18 0.2-1
IgM (g/L) 1.18 0.2-1.46
IgE (IU/mL) 6140 <200
Complement
C3 (g/L) 1.79 0.88-2.52
C4 (g/L) 0.12 0.12-0.72
Lymphocyte subsets
CD31 (cells/mL) 3560.6 2542-4933
CD31CD41 (cells/mL) 1900.4 1573-2949
CD31CD81 (cells/mL) 1413.9 656-1432
CD191 (cells/mL) 540.8 733-1338
NK cells (cells/mL) 211.83 186-724
NK, Natural killer.
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